scholarly journals FokI and BsmI Polymorphisms of the VDR Gene and Breast Cancer Risk

2016 ◽  
Vol 1 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Sasan Talaneh ◽  
Abolfazl Ghorbani ◽  
Tayebe Oghabi Bakhshaiesh ◽  
Behbuod Jafari
2014 ◽  
Vol 2 ◽  
Author(s):  
Ainur Akilzhanova ◽  
Zhannur Abilova ◽  
Nurgul Sikhayeva ◽  
Ivan Shtefanov ◽  
Abay Makishev ◽  
...  

Introduction: The steroid hormone 1,25-dihydroxyvitamin D3 is thought to protect against breast cancer. The activity of 1,25-dihydroxyvitamin D3 is mediated via the vitamin D receptor (VDR), and a number of polymorphisms in the VDR gene have been identified. These result in distinct genotypes, some of which may alter susceptibility to breast cancer. Two common single nucleotide polymorphisms (SNP) in the VDR gene (VDR), rs1544410 (BsmI) and rs2228570 (FokI), have been inconsistently associated with breast cancer risk. Increased risk has been reported for the FokI ff genotype, which encodes a less transcriptionally active isoform of VDR. A reduced risk has been reported for the BsmI BB genotype which may influence VDR mRNA stability.Aim: We have investigated whether specific VDR gene polymorphisms are associated with breast cancer risk in Kazakhstan women.Material and Methods: In a case–control study, female breast cancer patients (315) and a female control group (n=604) were tested for two VDR polymorphisms. Statistical analysis was conducted using SPSS19.0.Results: The VDR rs2228570 (FokI) polymorphism was associated with an increased occurence of BC [rs2228570 (folk) ff vs. FF genotype: OR=1.71; 95% CI=1.21-2.43]. No association was noted between rs1544410 (BsmI) BB and breast cancer risk [OR=0.68; 95% CI=0.49-0.95].Conclusion: Although the factors that increase breast cancer susceptibility remain uncertain, future large studies should integrate genetic variation in VDR with biomarkers of vitamin D status. Additional testing on the effect of varying genotypes on the functional mechanisms of the VDR could help to improve future testing and treatment of woman at risk for breast cancer.


Tumor Biology ◽  
2013 ◽  
Vol 35 (1) ◽  
pp. 93-102 ◽  
Author(s):  
Hua Wang ◽  
Wenjian Wang ◽  
Dongjie Yang ◽  
Shenming Wang

Swiss Surgery ◽  
2002 ◽  
Vol 8 (2) ◽  
pp. 45-52 ◽  
Author(s):  
Remmel ◽  
Harder

Prophylactic mastectomy is an aggressive strategy for breast cancer risk reduction. The indications and efficiency of this procedures are not yet clearly defined. Randomized, prospective studies, comparing different surgical procedures with other modalities of breast cancer risk reduction are lacking. The report evaluates the existing controversy, based on Medline search in the following sequence: risk factors, possibilities of risk reduction, effectiveness of risk reduction, technical considerations and recommendations. Patient selection is difficult and needs an interdisciplinary approach. The women have to be well informed about all treatment alternatives and various reconstructive procedures. An appropriate risk reduction strategy should be selected individually for each patient. Up to now, there exist only recommendations from different institutions but no definitive guidelines.


Sign in / Sign up

Export Citation Format

Share Document